Company
Headquarters: Billerica, MA, United States
Founded: 1960
Employees: 7,765
CEO: Dr. Frank H. Laukien Ph.D.
$6.43 Billion
USD as of July 1, 2025
Company | Market Cap (USD) |
---|---|
Abbott | $233.33 B |
Boston Scientific Corporation | $154.34 B |
Stryker | $151.06 B |
Medtronic | $113.25 B |
Edwards Lifesciences Corporation | $45.05 B |
Company | Market Cap (USD) |
---|---|
Lilly | $699.59 B |
Johnson & Johnson | $374.29 B |
AbbVie | $336.94 B |
Novo Nordisk | $309.91 B |
UnitedHealth Group | $279.90 B |
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Last Financial Reports Date | March 31, 2025 |
Revenue TTM | $3.45 B |
EBITDA | $571.2 M |
Gross Profit TTM | $1.72 B |
Profit Margin | 2.31% |
Operating Margin | 8.62% |
Quarterly Revenue Growth | 11.00% |
Bruker Corporation has the following listings and related stock indices.
Stock: NASDAQ: BRKR wb_incandescent
Stock: FSX: BKD wb_incandescent
Founder(s): Günther Laukien Emil Bruker
Frank Laukien, President & CEO; William Knight, COO